NEW YORK, July 23, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
A10 Networks, Inc. (NYSE: ATEN)
Class Period: February 9, 2016 - January 30, 2018
Lead Plaintiff Deadline: July 27, 2018
A10 Networks, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) A10 had issues with its internal controls that required an Audit Committee investigation; (2) A10's revenues since the fourth quarter of 2015 were false due to improper revenue recognition, which prompted an investigation by the Company’s Audit Committee; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.
To learn more about the ATEN class action go to: http://www.zlk.com/pslra-d/a10-networks-inc?wire=3 or email jlevi@levikorsinsky.com.
Fluor Corporation (NYSE: FLR)
Class Period: August 14, 2013 - May 3, 2018
Lead Plaintiff Deadline: July 24, 2018
During the class period, Fluor Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) Fluor’s bidding process for projects related to the construction of gas-fired power generation facilities was flawed; (ii) Fluor had improperly estimated the gas-fire projects; (iii) as a result, Fluor would face craft productivity issues, equipment issues and other execution issues; (iv) Fluor would incur multiple charges impacting quarterly results; and (v) Fluor would ultimately decide to discontinue the pursuit of the gas-fired power market.
To learn more about the FLR class action go to: http://www.zlk.com/pslra-d/fluor-class-action?wire=3 or email jlevi@levikorsinsky.com.
Recro Pharma, Inc. (NASDAQ: REPH)
Class Period: July 31, 2017 and May 23, 2018
Lead Plaintiff Deadline: July 30, 2018
According to the complaint (1) the Company's lead product, IV meloxicam, lacked supporting clinical data to show sufficient clinical benefits to receive U.S. Food and Drug Administration ("FDA") approval; and (2) as a result, Recro Pharma's public statements were materially false and misleading at all relevant times.
On May 24, 2018, Recro Pharma announced that the FDA had declined to approve its New Drug Application ("NDA") for IV meloxicam. In its Complete Response Letter, the FDA stated that the drug's analgesic effects did not meet FDA expectations and raised questions related to chemistry, manufacturing and controls data.
To learn more about the Recro Pharma class action go to: http://www.zlk.com/pslra-d/recro-pharma-inc?wire=3.
You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com